Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 0 Trial of RRx-001 for Glioblastoma Multiforme (GBM)

Next Previous
Search
Trial Profile

A Phase 0 Trial of RRx-001 for Glioblastoma Multiforme (GBM)

Status: Planning
Phase of Trial: Phase 0

Latest Information Update: 02 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nibrozetone (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors EpicentRx

    • Most Recent Events

    • 02 Dec 2019 New trial record
    • 25 Nov 2019 Accoridng to an EpicentRx media release, Howard Fine, M.D., (Director of Neuro-oncology at Weill Cornell Medical Center) is the principal investigator for this upcoming Phase 0 trial.This is a high priority project and collaboration for both Weill Cornell and EpicentRx.
    • 25 Nov 2019 Accoridng to an EpicentRx media release, the company plans to begin this Phase 0 trial of RRx-001 for GBM in the near future to gain further insight into the mechanism of action in brain tumors before starting Phase 3 studies.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top